ArticleProceedings of the National Academy of Sciences of the United States of America2022
Lots of long COVID treatment leads, but few are proven.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Melatonin, vitamins and minerals supplements for the treatment of Covid-19 and Covid-like illness: A prospective, randomized, double-blind multicenter study.Explore (New York, N.Y.)Trial
- Persistent health complications in COVID-19 hospitalized patients at tertiary care hospital in Western India.World journal of critical care medicine · 2026Article
- Long COVID-associated neurological symptoms and brain fog: Understanding the mechanism of neuroinflammation, BBB disruption, diagnostics, and therapeutics.Molecular biology reports · 2026Review
- Sociodemographic factors, biomarkers and comorbidities associated with post-acute COVID-19 sequelae in UK Biobank.Nature communications · 2025Article
- Modifiable lifestyle factors and the risk of post-COVID-19 multisystem sequelae, hospitalization, and death.Nature communications · 2024Article
- Type I interferon pathway genetic variants in severe COVID-19.Virus research · 2024Review
- Mechanisms of long COVID: An updated review.Chinese medical journal pulmonary and critical care medicine · 2023Review
- Article
- Brain Leukocytes as the Potential Therapeutic Target for Post-COVID-19 Brain Fog.Neurochemical research · 2023Article
- Long COVID: Costs for the German economy and health care and pension system.BMC health services research · 2023Article
- Patient and public involvement within epidemiological studies of long COVID in the UK.Nature medicine · 2023Article
- Corona With Lyme: A Long COVID Case Study.Cureus · 2023Article
- A review of cytokine-based pathophysiology of Long COVID symptoms.Frontiers in medicine · 2023Article
- Overview of the potential use of fluvoxamine for COVID-19 and long COVID.Discover mental health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.